Business

Emyria (ASX: EMD) has released its June 2026 quarterly update, highlighting strong revenue growth, national clinic expansion and encouraging early...

Newly rebranded BLS Pharmaceuticals (ASX:BLS) has capped off a transformational financial year, reporting record revenue, profitability and operating cash flow...

BLS Pharmaceuticals (ASX: BLS) has signed a referral agreement with US-based Cayman Chemical Company, expanding its international commercial network for...

Medicinal cannabis and psychedelic medicine are often discussed as part of the same healthcare revolution. Both involve substances that spent...

Global pharmaceutical giant Eli Lilly is reportedly in advanced discussions to acquire psychedelic drug developer AtaiBeckley, in what would become...

For much of the past decade, success in the cannabis and psychedelic sectors has been measured by one metric above...

Australia has earned global recognition for its role in the emerging psychedelic medicines sector. The country's decision to permit authorised...

Compass Pathways has reported positive six-month results from its second Phase 3 clinical trial evaluating COMP360 psilocybin treatment for treatment-resistant...

Australian biotechnology company Entropy Neurodynamics (ASX: ENP) has reported encouraging topline results from the first cohort of its Phase 2...

Red Light Holland subsidiary Filament Health will supply its naturally derived psilocybin drug candidate, PEX010, for a new clinical trial...